Media coverage about Aevi Genomic Medicine (NASDAQ:GNMX) has been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm scores the sentiment of press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Aevi Genomic Medicine earned a news sentiment score of 0.01 on Accern’s scale. Accern also assigned news coverage about the biotechnology company an impact score of 48.4287220613039 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Here are some of the media stories that may have impacted Accern’s analysis:
Several research analysts recently issued reports on GNMX shares. Needham & Company LLC cut their target price on shares of Aevi Genomic Medicine from $9.00 to $7.00 and set a “buy” rating for the company in a research report on Wednesday, August 16th. Jefferies Group reissued a “hold” rating and issued a $1.50 price target on shares of Aevi Genomic Medicine in a research note on Thursday, September 28th.
Aevi Genomic Medicine (NASDAQ GNMX) traded down $0.02 during trading on Friday, reaching $1.18. 189,950 shares of the company’s stock traded hands, compared to its average volume of 344,676. Aevi Genomic Medicine has a 1-year low of $0.98 and a 1-year high of $6.89.
Aevi Genomic Medicine (NASDAQ:GNMX) last posted its quarterly earnings results on Thursday, November 2nd. The biotechnology company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.01). During the same period last year, the company earned ($0.29) EPS. equities analysts anticipate that Aevi Genomic Medicine will post -0.88 EPS for the current fiscal year.
In other news, CEO Michael F. Cola acquired 119,047 shares of the stock in a transaction dated Tuesday, October 17th. The stock was purchased at an average cost of $1.26 per share, with a total value of $149,999.22. Following the completion of the purchase, the chief executive officer now owns 218,483 shares in the company, valued at approximately $275,288.58. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Sol J. Barer acquired 421,032 shares of the stock in a transaction dated Tuesday, October 17th. The shares were purchased at an average cost of $1.26 per share, with a total value of $530,500.32. Following the completion of the purchase, the director now owns 1,028,032 shares of the company’s stock, valued at approximately $1,295,320.32. The disclosure for this purchase can be found here. Over the last ninety days, insiders have bought 615,079 shares of company stock valued at $775,000. Insiders own 15.20% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This report was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another website, it was copied illegally and reposted in violation of U.S. and international copyright and trademark law. The original version of this report can be read at https://www.dispatchtribunal.com/2017/12/09/aevi-genomic-medicine-gnmx-earns-daily-news-sentiment-score-of-0-01.html.
About Aevi Genomic Medicine
Aevi Genomic Medicine, Inc, a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. Its lead product candidates include AEVI-001, a glutamatergic neuromodulator, which is in Phase II/III SAGA trial for a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients with specific mutations in their metabotropic glutamate receptor gene network; and AEVI-002, an anti-light monoclonal antibody that is in Phase I clinical trial for use in severe pediatric onset crohns disease.
Receive News & Ratings for Aevi Genomic Medicine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aevi Genomic Medicine Inc. and related companies with MarketBeat.com's FREE daily email newsletter.